Related references
Note: Only part of the references are listed.Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Yi-Sheng Chang et al.
SCIENTIFIC REPORTS (2018)
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Jialiang Zhao et al.
BIODRUGS (2014)
Prevalence and risk factors for age-related macular degeneration in the elderly Chinese population in south-western Taiwan: the Puzih eye study
E. J-C Huang et al.
EYE (2014)
The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab Injections
Adnan Tufail et al.
OPHTHALMOLOGY (2014)
Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany
Robert P. Finger et al.
ACTA OPHTHALMOLOGICA (2013)
CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE The LUMIERE Study
Salomon Y. Cohen et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
EXTEND III: Efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD
Oh-Woong Kwon et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2012)
Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study
Yasuo Tano et al.
ACTA OPHTHALMOLOGICA (2011)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
Yasuo Tano et al.
ACTA OPHTHALMOLOGICA (2010)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Risk factors for incident age-related macular degeneration - Pooled findings from 3 continents
SC Tomany et al.
OPHTHALMOLOGY (2004)
Share Paper
